OBJECTIVE: We conducted a phase II multicenter trial of perillyl alcohol in patients with advanced hormone refractory prostate cancer (HRPC). The primary endpoint was to evaluate the 6-month progression-free survival given the potential cytostatic nature of the drug. Secondary objectives included assessing acute and chronic toxicities, as well as measuring objective response rates. METHODS:Patients with metastatic androgen-independent prostate cancer that failed at least one prior chemotherapeutic or experimental regimen were eligible. Perillyl alcohol was administered orally at 1200 mg/m2/dose four times daily and continued until disease progression or development of unacceptable toxicity. RESULTS:Fifteen patients were eligible. Six patients received less than one cycle (4 weeks) of drug, four of which stopped because of drug intolerance. Only six patients received more than two cycles of therapy and were considered evaluable for response. Main toxicity included grade 1-2 gastrointestinal intolerance (nausea/vomiting in 60% of the patients) and fatigue (47%). One patient developed a grade 4 hypokalemia that was felt likely attributable to the drug. No objective responses were seen. All patients either progressed or withdrew from the study secondary to drug intolerance before the 6-month time period. CONCLUSION:Perillyl alcohol administered at this dose and formulation did not have any objective clinical activity in this patient population.
RCT Entities:
OBJECTIVE: We conducted a phase II multicenter trial of perillyl alcohol in patients with advanced hormone refractory prostate cancer (HRPC). The primary endpoint was to evaluate the 6-month progression-free survival given the potential cytostatic nature of the drug. Secondary objectives included assessing acute and chronic toxicities, as well as measuring objective response rates. METHODS:Patients with metastatic androgen-independent prostate cancer that failed at least one prior chemotherapeutic or experimental regimen were eligible. Perillyl alcohol was administered orally at 1200 mg/m2/dose four times daily and continued until disease progression or development of unacceptable toxicity. RESULTS: Fifteen patients were eligible. Six patients received less than one cycle (4 weeks) of drug, four of which stopped because of drug intolerance. Only six patients received more than two cycles of therapy and were considered evaluable for response. Main toxicity included grade 1-2 gastrointestinal intolerance (nausea/vomiting in 60% of the patients) and fatigue (47%). One patient developed a grade 4 hypokalemia that was felt likely attributable to the drug. No objective responses were seen. All patients either progressed or withdrew from the study secondary to drug intolerance before the 6-month time period. CONCLUSION:Perillyl alcohol administered at this dose and formulation did not have any objective clinical activity in this patient population.
Authors: I F Tannock; D Osoba; M R Stockler; D S Ernst; A J Neville; M J Moore; G R Armitage; J J Wilson; P M Venner; C M Coppin; K C Murphy Journal: J Clin Oncol Date: 1996-06 Impact factor: 44.544
Authors: G R Hudes; C E Szarka; A Adams; S Ranganathan; R A McCauley; L M Weiner; C J Langer; S Litwin; G Yeslow; T Halberr; M Qian; J M Gallo Journal: Clin Cancer Res Date: 2000-08 Impact factor: 12.531
Authors: P W Kantoff; S Halabi; M Conaway; J Picus; J Kirshner; V Hars; D Trump; E P Winer; N J Vogelzang Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Howard H Bailey; Donna Levy; Linda S Harris; Julian C Schink; Francine Foss; Peter Beatty; Scott Wadler Journal: Gynecol Oncol Date: 2002-06 Impact factor: 5.482
Authors: Nitin S Nandurkar; Jianjun Zhang; Qing Ye; Larissa V Ponomareva; Qing-Bai She; Jon S Thorson Journal: J Med Chem Date: 2014-08-25 Impact factor: 7.446
Authors: Axel H Schönthal; David M Peereboom; Naveed Wagle; Rose Lai; Anna J Mathew; Kyle M Hurth; Vincent F Simmon; Steven P Howard; Lynne P Taylor; Frances Chow; Clovis O da Fonseca; Thomas C Chen Journal: Neurooncol Adv Date: 2021-02-12